The objective of the City of Hope (COH) Clinical Oncology Research Career Development Program is to develop a new generation of clinical oncologic investigators capable of translating basic advances in cancer biology into novel strategies for the diagnosis, therapy, and prevention of malignant disease. This multidisciplinary effort will be available to outstanding surgeons, radiation oncologists, pathologists, pediatricians, and internists who have completed their fellowship training in oncology no more than 3 years previously, and who are appropriate for appointment to the faculty of the COH Cancer Research Center. Over the past fifteen years, the COH has pursued as one of its central goals, the enhancement of interactive basic and clinical research at the cutting edge of molecular biology, protein chemistry, immunology, bone marrow transplantation, and experimental therapeutics. During this time, 64 physicians have completed fellowships in surgical oncology, medical oncology, and surgical or hematopathology at COH; 37 of these 64 physicians have pursued full-time academical positions in clinical oncologic investigation. In this proposal, we describe a four-year curriculum which involves both didactic and """"""""hands on"""""""" experiences in biostatistics, clinical investigation, basic science and laboratory research for training clinical investigators at the Junior faculty level. During the first year, the core curriculum involves three 4 month rotations in the laboratories of senior investigators in molecular biology, immunology, tumor biology, virology, experimental therapeutics, or hematologic malignancy as well as 7 hours per week of lectures and discussion. Trainees will be supervised by both clinical and laboratory mentors throughout the entire 4 years of the program. In years 2 through 4, trainees will be involved in 2 hours per week of dedicated research seminars and journal clubs that will be an integral part of their supervised laboratory program in which they spend 28 hours per week. The activities of the trainees will be carefully assessed every 4 months in writing during the first year and at the end of years 2, 3, and 4. Furthermore, trainees will present progress reports orally to the Internal Advisory Committee of the program twice per year. Requirements for satisfactory completion of the clinical oncology career development program include the publication of a report of the trainee's clinical and laboratory research in a peer-reviewed journal, and the completion of both a clinical research protocol which the trainee will pursue during years 2 through 4, and a grant application detailing an appropriate combined clinical and laboratory study that is suitable for submission to the National Institutes of Health.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
3K12CA001727-10S1
Application #
6617555
Study Section
Special Emphasis Panel (ZCA1 (01))
Program Officer
Lei, Ming
Project Start
1992-09-09
Project End
2003-06-30
Budget Start
2002-07-01
Budget End
2003-06-30
Support Year
10
Fiscal Year
2002
Total Cost
$290,734
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
City
Duarte
State
CA
Country
United States
Zip Code
91010
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520
Chuang, Jeremy; Gong, Jun; Klempner, Samuel J et al. (2018) Refining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classification. J Gastrointest Oncol 9:560-572
Konstantinidis, Ioannis T; Jutric, Zeljka; Eng, Oliver S et al. (2018) Robotic total pancreatectomy with splenectomy: technique and outcomes. Surg Endosc 32:3691-3696
LaRocca, Christopher J; Wong, Paul; Eng, Oliver S et al. (2018) Academic productivity in surgical oncology: Where is the bar set for those training the next generation? J Surg Oncol 118:397-402
Herrera, A F; Palmer, J; Martin, P et al. (2018) Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol 29:724-730
Zhang, Keqiang; Wang, Jinhui; Yang, Lu et al. (2018) Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1? and APC2 gene expression in non-small cell lung cancer. Mol Cancer 17:153
Wolfson, Julie A; Richman, Joshua S; Sun, Can-Lan et al. (2018) Causes of Inferior Outcome in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: Across Oncology Services and Regardless of Clinical Trial Enrollment. Cancer Epidemiol Biomarkers Prev 27:1133-1141
Lin, Emily M; Gong, Jun; Klempner, Samuel J et al. (2018) Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond. World J Gastroenterol 24:2686-2697
Raoof, Mustafa; Nota, Carolijn L M A; Melstrom, Laleh G et al. (2018) Oncologic outcomes after robot-assisted versus laparoscopic distal pancreatectomy: Analysis of the National Cancer Database. J Surg Oncol 118:651-656
Yun, Xinwei; Zhang, Keqiang; Wang, Jinhui et al. (2018) Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma. Mol Cancer Res 16:1161-1171

Showing the most recent 10 out of 192 publications